11.61
0.77%
-0.09
After Hours:
11.21
-0.40
-3.45%
Eyepoint Pharmaceuticals Inc stock is traded at $11.61, with a volume of 414.57K.
It is down -0.77% in the last 24 hours and up +34.53% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$11.70
Open:
$11.53
24h Volume:
414.57K
Relative Volume:
0.58
Market Cap:
$791.27M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-4.117
EPS:
-2.82
Net Cash Flow:
$-1.61M
1W Performance:
+0.61%
1M Performance:
+34.53%
6M Performance:
-41.19%
1Y Performance:
+49.81%
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-22-24 | Initiated | JP Morgan | Overweight |
Nov-02-23 | Initiated | Mizuho | Buy |
Apr-21-23 | Initiated | Robert W. Baird | Outperform |
Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
Mar-01-21 | Initiated | Cowen | Outperform |
Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
Nov-04-19 | Resumed | Laidlaw | Buy |
Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Scrip
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in EyePoint Pharmaceu - GuruFocus.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.4%Here's What Happened - MarketBeat
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Pharmaceuticals Announces Successful Closure of Underwritten Public Offering WATERTOWN, Mass., October 31, 2024 – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently finalized its underwritten public offering of 14,636,363 shares - Defense World
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
When (EYPT) Moves Investors should Listen - Stock Traders Daily
EyePoint rises on interim data for mid-stage trial of its diabetic macular edema therapy - MSN
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - The Manila Times
EyePoint Pharmaceuticals prices $140M share offering - MSN
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? - MSN
Guggenheim maintains Buy on EyePoint with $68 target - Investing.com India
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - The Manila Times
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5%Should You Sell? - MarketBeat
EyePoint launches $100 million public stock offering By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass. - The Business Journals
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
EyePoint shares hold as analyst reiterates Buy rating By Investing.com - Investing.com South Africa
EyePoint reports positive DURAVYU trial results for DME By Investing.com - Investing.com South Africa
EyePoint launches $100 million public stock offering - Investing.com India
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times
Guggenheim maintains Buy on EyePoint with $68 target By Investing.com - Investing.com UK
EyePoint reports positive DURAVYU trial results for DME - Investing.com India
EyePoint shares hold as analyst reiterates Buy rating - Investing.com
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss - Yahoo Finance
EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu - MarketWatch
EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - The Manila Times
EyePoint stock gains traction with new AMD trials, Jefferies sees 65% upside - Investing.com Canada
EyePoint announces $175 million stock offering following record surge in share price - MSN
Analyst Ratings For EyePoint Pharmaceuticals - Benzinga
EyePoint stock gains traction with new AMD trials, Jefferies sees 65% upside By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (NASDAQ:EYPT) Given Buy Rating at HC Wainwright - MarketBeat
SG Americas Securities LLC Sells 56,985 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint begins Phase 3 trial for wet AMD treatment By Investing.com - Investing.com Australia
Laidlaw keeps Buy rating, $50 target on EyePoint Pharmaceuticals - Investing.com
Laidlaw keeps Buy rating, $50 target on EyePoint Pharmaceuticals By Investing.com - Investing.com Canada
Alphabet Cl A (GOOGL-Q) QuotePress Release - The Globe and Mail
EyePoint begins Phase 3 trial for wet AMD treatment - Investing.com
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration - StockTitan
AAO 2024: EyePoint’s EYP-1901 proves non-inferiority to aflibercept in DAVIO 2 - Pharmaceutical Technology
(EYPT) Investment Analysis and Advice - Stock Traders Daily
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):